Xiidra® (5% lifitegrast ophthalmic solution)

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease ChamberNCT05102409ALDXPhase 2Completed2021-10-25Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.